Ablynx opens new R&D facility

Pharma group expands research operation

Ablynx, a biopharmaceutical company focused on the discovery and development of nanobodies, has expanded into new research and development facilities located on the Technologiepark in Zwijnaarde, near Ghent.

Ablynx is developing a nanobody-based portfolio of therapeutics in a number of therapeutic areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Ablynx has over 25 programmes in its therapeutic pipeline including four Nanobodies in clinical development.